PRRT2 and neoplasm: Recent advancements in cancer treatment strategies have explored the modulation of PKC signaling, utilizing activators like Bryostatins (103) and Epoxytiglianes (104–106), as well as inhibitors such as CGP 41251, to counteract tumor growth and reverse multidrug resistance (107).